The Recall Desk
ModerateFDA (Drugs)·D-0335-2025·Announced 2025-04-16

Drug Recall: Ranolazine Extended-Release Tablets Due to Manufacturing Deviations

Glenmark Pharmaceuticals is recalling Ranolazine Extended-Release 1000mg tablets (Lot 17240040) nationwide due to manufacturing deviations. This is a voluntary, firm-initiated recall.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: This is a Class II voluntary recall initiated by the manufacturer with no reported illnesses, injuries, or deaths. The recall is precautionary, based on manufacturing deviations without detailed hazard specifications.

Plain-English summary

Glenmark Pharmaceuticals Inc., USA is recalling Ranolazine Extended-Release Tablets 1000mg in 60-count bottles (Lot #17240040, expiration December 2025, NDC# 68462-320-60) distributed nationwide.

The recall is due to Current Good Manufacturing Practice (CGMP) deviations identified during the manufacturing process.

Consumers with affected medication should consult their healthcare provider or pharmacist regarding this recall.

The recalled product

Product
RANOLAZINE (RANOLAZINE)
Brand
RANOLAZINE
Manufacturer
Glenmark Pharmaceuticals Inc., USA
Category
Drug
Hazard
  • manufacturing-defect

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot # 17240040
  • exp. date Dec-25

UPCs (2)

  • 0368462320600
  • 0368462319604

Distribution

Distributed nationwide across the United States.

Related recalls

Same brand · RANOLAZINE

Same category